UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 OR 15 (dD) ofOF ~~the Securities Exchange Act of 1934~~THE

~~Date~~SECURITIES ofEXCHANGE ~~Report~~ACT ~~(Date~~OF ~~of earliest event reported): January 26, 2015~~1934

~~NUTRANOMICS,~~Date ~~INC.~~of Report (~~Exact~~Date ~~name~~ of ~~registrant~~earliest asevent ~~specified~~reported): September in29, ~~its charter)~~2015

Nevada		000-53551		98-0603540
(state or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

NUTRANOMICS, INC.

11487 South 700 East Salt Lake City, UT		84020
(address of principal executive offices)		(zip code)

(Exact name of registrant as specified in its charter)

~~(801) 576-8350 (registrant's telephone number, including area code)~~Nevada

~~Not Applicable~~ (~~former~~State ~~name~~ or ~~former~~Other ~~address,~~Jurisdiction ifof ~~changed since last report~~Incorporation)

000-53551	98-0603540
(Commission File Number)	(IRS Employer Identification No.)

11487 South 700 East, Salt Lake City, UT	84020
(Address of Principal Executive Offices)	(Zip Code)

(801) 576-8350

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~[ ~~1.01 Entry~~] Soliciting ~~into~~material apursuant ~~Definitive~~to ~~Material~~Rule ~~Agreement~~14a-12 under the Exchange Act (17 CFR 240.14a-12)

On[ ~~January~~] Pre-commencement ~~26,~~communications ~~2015,~~pursuant ~~Nutranomics,~~to ~~Inc.~~Rule 14d-2(~~the "Company"~~b) ~~entered~~under ~~into~~the ~~a Share~~ Exchange ~~Agreement~~Act ~~with~~(17 ~~Nutriband~~CFR ~~Ltd~~240.~~, an Irish private limited company~~ 14d-2(~~"Nutriband"~~b)~~, and its shareholders to acquire 100% of Nutriband in exchange for (1~~) the issuance of 3,172,554 shares of the Company's common stock to Nutriband's shareholder, Gareth Sheridan, and (2) the payment of a perpetual 10% royalty on gross global sales of all Nutriband products to the Nutriband shareholders.

~~Also~~[ on] Pre-commencement ~~January~~communications ~~26,~~pursuant ~~2015, the Company's subsidiary, Health Education Corporation d/b/a Nutranomics ("Nutranomics") entered into a Bill of Sale and Assignment (the "Assignment")~~ to ~~purchase~~Rule ~~from Dr. Tracy Gibbs, our former CEO and current director, 100% of his rights, title and interest in and to the Assimilation Enhancing System~~ 13e-4(~~AES™~~c) and related patent (US Patent Number 7,235,390) and intellectual property, in exchange for the issuance of 44,117,647 shares of the Company's common stock. The Assignment terminates the AES License and Royalty Agreement between Nutranomics and Dr. Gibbs dated as of June 14, 2007, and the issuance of the shares to Dr. Gibbs under the ~~assignment~~Exchange ~~satisfies~~Act in(17 ~~total~~CFR ~~any outstanding royalties owed to Dr~~240. ~~Gibbs. The AES™ is a combination of enzymes and their co~~13e-~~factors that are designed to break down or digest nutrients more quickly so that the nutrients can be absorbed faster and more completely into the blood stream than if the AES™ were not present.~~4(c))

~~The~~Item ~~foregoing~~5.02 Departure ~~descriptions~~ of ~~the~~Directors ~~Share~~or ~~Exchange~~Principal ~~Agreement~~Officers; ~~and~~Election ~~Assignment,~~of ~~and~~Directors; ~~the~~Appointment ~~terms thereof, are qualified in their entirety by the full text~~ of ~~such~~Principal ~~agreements, which are filed as Exhibits 10~~Officers.~~1 and 10.2 to, and incorporated by reference in, this report.~~

~~Item~~On ~~2.01 Completion~~September 29, 2015, Michael Doron resigned from all officer positions and as a director of ~~Acquisition~~Nutranomics, orInc. ~~Disposition~~(the “Company”), and Edward J. Eyring, II, M.D., was appointed as Chief Executive Officer, Chief Financial Officer, and Secretary of ~~Assets~~the Company.

OnEdward ~~January~~“Joe” 29Eyring, ~~2015~~II, ~~the~~M.D., ~~Company~~age ~~completed~~48 ~~the~~is ~~acquisitions~~a ofpreviously ~~Nutriband~~Board-certified colorectal surgeon and successful entrepreneur in the ~~AES™~~healthcare ~~intellectual~~industry ~~property~~with ~~described~~an inextensive ~~Item~~and 1successful record of practice and business development.01 ~~above~~By bythe ~~issuing~~time ~~(1)~~he ~~3,172,554~~entered ~~shares~~medical ofschool in the ~~Company'~~late 1980’s, ~~common~~Dr. ~~stock~~Eyring tohad ~~Gareth~~already ~~Sheridan,~~spent ~~and~~nearly ~~(2)~~a 44decade apprenticing with his father,~~117,647~~ ~~shares~~an oforthopedic ~~the~~surgeon ~~Company's~~who ~~common~~treated ~~stock~~orphaned tochildren Drin developing nations. ~~Gibbs's~~A ~~family~~fascination ~~partnership~~with medicine, coupled with the ~~Zen~~satisfaction ~~Family~~of LPhelping people in need, ignited his interest in public service.

~~Item~~By 3the time he became a licensed physician in 1994, Dr.~~02 Unregistered~~ ~~Sales~~Eyring had already learned first-hand about the calamity of ~~Equity~~disease ~~Securities~~progression in patients with limited access to preventative care or treatment. Inspired by these experiences, he embarked upon his medical career with a long-range vision toward making quality medical care affordable and accessible to anyone.

~~The~~During ~~information~~13 ~~set~~years ~~forth~~as ina ~~Items~~colorectal 1surgeon, Dr.01 ~~and~~Eyring ~~2.01~~witnessed ~~above~~devastating ~~regarding~~results ~~the~~of ~~Company's~~insufficient ~~issuance~~access ofto ~~shares~~preventative ofcare ~~common~~or ~~stock~~treatment. He had an opportunity to ~~Gareth~~work ~~Sheridan~~with a naturopathic medical doctor and ~~Dr.~~learned ~~Gibbs~~benefits isof ~~hereby~~a ~~incorporated~~more ~~into~~integrative, ~~this~~holistic ~~Item~~approach 3to disease prevention and cure.~~02.~~

OnAs ~~January~~a ~~26,~~medical ~~2015~~entrepreneur, ~~the~~Dr. ~~Company~~Eyring ~~issued~~gained ~~2,586,207~~first-hand ~~shares~~knowledge of ~~the~~how ~~Company's~~rate ~~common~~structures ~~stock~~also toimpacted ~~KBM~~health ~~Worldwide,~~outcomes; ~~Inc.~~those ~~("KBM"),~~without ininsurance ~~partial~~either ~~satisfaction~~went ofdeeply ~~its~~into ~~obligations~~debt ~~under,~~or ~~and~~without ~~the~~treatment ~~holder's~~altogether. ~~election~~The todisparity ~~convert~~strengthened ahis ~~portion~~resolve ~~of,~~to bridge the ~~Convertible~~gap ~~Promissory~~in ~~Note~~coverage ~~dated~~and ~~March~~provide ~~19,~~equal ~~2014,~~opportunity ~~with~~for ananyone ~~original~~to ~~principal~~maintain ~~amount~~good ~~of $53,000 and held by KBM~~health.

OnSince ~~January 29~~2014, ~~2015~~Dr. Eyring has been Managing Director of Domaine Global LLC; from 2010-2013, Dr. Eyring was the ~~Company~~Founder, ~~issued~~CEO 5and Chair of Simplify Rx,~~000~~ Inc.; in 2013,~~000~~ ~~shares~~Dr. ofEyring ~~the~~was a Medical Director at Aeromedical Collection Services; in 2014, Dr. Eyring founded American Recovery Company's, ~~common~~which ~~stock~~he tohas ~~Alta~~operated ~~Nordic~~until ~~LLC~~the present date; from 2004-2013, anDr. ~~entity~~Eyring ~~controlled~~was bythe ~~Michael~~founding ~~Doron~~partner and Medical Director of Physicians Pharmaceutical Services; from 2005-2012, ~~our~~Dr. ~~CEO~~Eyring was the owner and ~~director~~principal researcher of Synergies Medical Research, inLLC; ~~consideration~~from ~~for~~2000-2013, MrDr. ~~Doron's~~Eyring ~~previous~~was ~~appointment~~a tosurgeon and Founding Practice Leader at Integrative GI Healthcare; and from 2000-2012, Dr. Eyring was the ~~Company's~~sole ~~Board~~proprietor of ~~Directors~~the Pelvic Floor Diagnostic Center in Murray, Utah.

OnPursuant ~~January~~to Dr. Eyring’s employment contract with the Company, entered into on September 29, 2015, Dr. Eyring will be compensated in the amount of $160,000 per year, which shall be accrued until January 1, 2016. At such time, it will be paid in full or converted into Company ~~issued~~common 2stock at the previous 5-day volume weighted average price at such time. As of January 1,~~500~~ 2016, Dr. Eyring’s annual compensation shall increase to $260,000 ~~shares~~per ofyear if the Company'’s ~~common~~revenues ~~stock~~during the October 1, 2015-December 31, 2015 period increase two-fold as compared the same period during 2014. Otherwise, his annual compensation shall remain at $160,000 per year. If his annual compensation does increase to ~~Alta~~$260,000 ~~Nordic~~per ~~LLC~~year, $160,000 shall be paid in ~~consideration~~stock ~~for~~on Mra quarterly basis valued at the previous 5-day VWAP at the time of issuance, with the balance paid in cash. Dr. ~~Doron's~~Eyring ~~negotiation~~will also receive an additional equity award during the first year of employment equal to 0.83% of the issued and ~~closing~~outstanding common stock of the ~~Nutriband~~Company ~~acquisition~~following the completion of each month of employment during the first year. The employment contract is terminable at the election of either party without cause upon the provision of 30 days’ notice to the other, and is terminable by the Company for cause at any time.

On January 29, 2015, the Company issued 30,157,463 shares of the Company's common stock to Alta Nordic LLC in satisfaction of the Company's obligations to Mr. Doron under the Company's employment contract with Mr. Doron.

On January 29, 2015, the Company issued 5,768,280 shares of the Company's common stock to Chienn Consulting Company for general business and marketing consulting services rendered during the quarter.

The securities issued above were issued pursuant to exemptions from registration requirements relying on Section 4(2) of the Securities Act of 1933 and upon Rule 506 of Regulation D of the Securities Act of 1933.

Item 9.01 Financial Statements and Exhibits

The exhibits listed in the following Exhibit Index are filed as part of this report:

10.1 Agreement for Share Exchange dated January 26, 2015

10.2 Bill of Sale and Assignment dated January 26, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~thereunto duly authorized.

	Nutranomics, Inc.
Dated: January 30, 2015	/s/ Michael Doron
	Michael Doron
	Chief Executive Officer, Chief Financial Officer & Director

Date: October 5, 2015

	NUTRANOMICS, INC.

	By: /s/ Edward J. Eyring, II
	Edward J. Eyring, II
	Chief Executive Officer

Filing Compare · NUTRANOMICS, INC.